Eli Lilly has announced plans to acquire Orna Therapeutics, a biotechnology company specializing in in vivo CAR-T therapies targeting autoimmune diseases. The deal is valued at approximately $2.4 billion.
Orna Therapeutics develops novel treatments that use engineered RNA to reprogram immune cells directly within the body. This acquisition is expected to expand Eli Lilly’s portfolio in the autoimmune disease space and advance its capabilities in cell therapy.
**Why this matters**
The acquisition highlights growing interest in in vivo CAR-T technology as a potential approach for treating autoimmune conditions. By integrating Orna’s platform, Eli Lilly aims to accelerate the development of innovative therapies that could offer new options for patients with diseases that currently have limited treatment choices.
Source: NewsData